Anteris Technologies (AVR) Q1 2025 earnings summary

Executive summary

• Focused on developing the DurAVR THV system for aortic stenosis, leveraging proprietary ADAPT tissue technology, and expanding manufacturing capacity for pivotal clinical trials.

• Completed a U.S. IPO in December 2024, raising $80 million net proceeds, and executed a corporate reorganization to become a Delaware corporation.

• Submitted IDE for the pivotal PARADIGM Trial of DurAVRⓇ THV to the FDA during Q1 2025, with trial commencement targeted for Q3 2025 pending approval.

• Over 100 patients treated with DurAVR THV system globally as of March 31, 2025, including complex anatomies and valve-in-valve cases.

• Released one-year clinical data showing sustained favorable hemodynamics, consistent safety, and high implant success.

Financial highlights

• Net sales for Q1 2025 were $0.6 million, down 27% year-over-year due to lower tissue product demand.

• Net loss for Q1 2025 was $21.9 million, a 36% increase from Q1 2024, driven by higher R&D and trial preparation costs.

• R&D expenses rose 42% to $16.5 million, reflecting manufacturing scale-up and clinical trial preparation.

• SG&A expenses decreased 13% to $5.7 million, reflecting lower IPO-related costs, partially offset by higher compliance expenses.

• Cash and cash equivalents were $49.0 million as of March 31, 2025, down from $70.5 million at year-end 2024.

Outlook and guidance

• Expects continued substantial losses and negative cash flows until regulatory approvals and commercialization of DurAVR THV system.

• Additional capital will be required to fund operations and achieve long-term goals; current cash is not sufficient for the next 12 months.

• No significant revenue expected until after regulatory approvals and product launch.

• On track to begin the PARADIGM Trial in Q3 2025, pending FDA IDE approval.

• Continued investment in clinical, manufacturing, and quality teams to support trial and future commercialization.